Health & Fitness
Health and Fitness
Health and Fitness
Tue, July 17, 2012Mon, July 16, 2012Fri, July 13, 2012Thu, July 12, 2012Wed, July 11, 2012Tue, July 10, 2012Mon, July 9, 2012Fri, July 6, 2012Thu, July 5, 2012Wed, July 4, 2012Tue, July 3, 2012Mon, July 2, 2012Sun, July 1, 2012Fri, June 29, 2012Thu, June 28, 2012Wed, June 27, 2012Tue, June 26, 2012Mon, June 25, 2012Sun, June 24, 2012Sat, June 23, 2012Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
Published in Health and Fitness on Thursday, July 5th 2012 at 5:42 GMT by Market Wire
Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference -- SAN DIEGO, July 5, 2012 /PRNewswire/ --
Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
SAN DIEGO, July 5, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) today announced that the Company will present at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12 at 10:30 a.m. Eastern Time in New York, NY, and provide a business overview and update.
(Logo: [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ])
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at [ www.optimerpharma.com ]. Replays of the presentation will be available at the same location for 90 days following the presentation.
About Optimer Pharmaceuticals Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD) and is commercializing DIFICID in the US and Canada. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].
Contacts Optimer Pharmaceuticals, Inc. David Walsey, VP of Investor Relations and Corporate Communications (858) 964-3418
Canale Communications Jason I. Spark, Senior Vice President 619-849-6005 [ Jason@canalecomm.com ]
OPTIMER and DIFICID are trademarks of Optimer Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
SOURCE Optimer Pharmaceuticals, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.optimerpharma.com ]
